Physician profile
Jonathan Joseph
NPI 1285637645
$6,835.97
in general payments reported to CMS, 2019-2025
30 companies · $1,330 in 2025
The $1,330 reported for 2025 was more than what 83% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $405 · 2020: $121 · 2021: $1,130 · 2022: $1,084 · 2023: $1,325 · 2024: $1,442 · 2025: $1,330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,997 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,996.78 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,229.88 | 2019-2025 | Tryptyr, Clareon, Simbrinza |
| Oyster Point Pharma, INC. | $1,083.58 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Johnson & Johnson Surgical Vision, INC. | $661.17 | 2019-2025 | Tecnis Iol, Tecnis Iol, Tecnis Simplicity |
| Rxsight INC | $552.38 | 2021-2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Bausch & Lomb Americas INC. | $464.64 | 2023-2025 | Xiidra, Miebo, Vyzulta |
| Abbvie INC. | $316.90 | 2022-2025 | |
| Tarsus Pharmaceuticals, INC. | $241.14 | 2024-2025 | Xdemvy |
| Biotissue Holdings INC. | $238.51 | 2022-2025 | |
| Allergan, INC. | $232.46 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $231.67 | 2023-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $206.80 | 2019-2023 | |
| Galderma Laboratories, L.P. | $203.63 | 2024 | |
| Harrow Eye, LLC | $180.41 | 2024-2025 | Vevye |
| Sun Pharmaceutical Industries INC. | $152.23 | 2022-2025 | |
| Johnson & Johnson Vision Care, INC. | $147.50 | 2022-2023 | Acuvue |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $114.21 | 2019-2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $109.74 | 2024 | Altreno, Cabtreo, Arazlo |
| Shire North American Group INC | $68.52 | 2019 | |
| Ucb, INC. | $66.83 | 2025 | Bimzelx |
| Dompe US, INC. | $59.27 | 2025 | Oxervate |
| Janssen Biotech, INC. | $58.48 | 2024 | Tremfya |
| Glaukos Corporation | $45.54 | 2024 | Idose |
| Ocular Therapeutix, INC. | $29.74 | 2022-2025 | Dextenza |
| Leo Pharma INC. | $24.48 | 2024 | Adbry |
| Rayner Intraocular Lenses Limited | $23.18 | 2025 | Omidria |
| E.R. Squibb & Sons, L.L.C. | $20.87 | 2024 | Sotyktu |
| Beaver-Visitec International, INC. | $19.51 | 2019 | |
| Amgen INC. | $18.61 | 2024 | Tepezza |
| Horizon Therapeutics Plc | $17.08 | 2023 | Tepezza |
| Eyevance Pharmaceuticals LLC | $17.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Joseph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.